Splash Expands CannEpil License for Veterinary Therapeutic Applications
Splash Beverage Group announced the expansion of its exclusive global license for CannEpil to include veterinary therapeutic applications, establishing a second pharmaceutical development platform. The company plans to initially evaluate CannEpil for companion-animal oncology and chronic pain management, with a focus on canine indications, and will seek U.S. regulatory approval via the FDA Center for Veterinary Medicine. This move positions CannEpil in significant and growing markets, with the global veterinary pain management market projected to reach $3.8 billion by 2030 and the veterinary oncology market estimated between $900 million and $1.7 billion. Splash is also finalizing a strategic joint venture with an established cannabinoid pharmaceutical company to lead the veterinary development program.
Key Highlights
- Splash expanded its exclusive global license for CannEpil to veterinary therapeutic applications.
- This creates a second regulated pharmaceutical development platform for the company.
- Initial evaluation for companion-animal oncology and chronic pain management, focusing on canines.
- Splash will pursue U.S. regulatory approval through the FDA Center for Veterinary Medicine.
- Global veterinary pain management market projected to reach $3.8 billion by 2030.
- Global veterinary oncology market estimated between $900 million and $1.7 billion.
- Splash is finalizing a strategic joint venture for CannEpil's veterinary development program.
- Splash will pay Argent BioPharma Limited a 10% royalty on net veterinary revenues.
Price Impact
More from SBEV